$VYGR News

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President

Voyager Therapeutics Appoints Robin Swartz As President, Effective October 20, And Is Expected To Become CEO In Q1 2027

Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Voyager to Present at Upcoming Investor Conferences

HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Reports Second Quarter 2026 Financial and Operating Results

Voyager Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate, Sales $3.165M Miss $4.728M Estimate

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Voyager Therapeutics Presents Six‑Month Toxicology Data At AAIC Showing Investigational Alzheimer’s Gene Therapy VY1706 Was Well Tolerated And Cut Tau Protein Up To 75% In Primates

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

Voyager Therapeutics Issued FDA Clearance For Its Investigational New Drug Application For VY1706 To Treat Alzheimer's Disease

What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

Voyager Reports First Quarter 2026 Financial and Operating Results

Voyager Therapeutics Q1 EPS $(0.47) Beats $(0.53) Estimate, Sales $2.593M Miss $8.784M Estimate